Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ultragenyx Pharmaceutical Inc RARE

Healthcare Biotechnology
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product... see more

Recent & Breaking News (NDAQ:RARE)

Ultragenyx Announces Crysvita® (burosumab) and UX143 (setrusumab) Data Presentations at Upcoming American Society for Bone and Mineral Research (ASBMR) 2021 Annual Meeting

GlobeNewswire September 27, 2021

GeneTx and Ultragenyx Announce FDA has Removed Clinical Hold on Phase 1/2 Clinical Study of GTX-102 for the Treatment of Angelman Syndrome in the U.S.

GlobeNewswire September 27, 2021

Ultragenyx to Present at Morgan Stanley Healthcare Conference

GlobeNewswire September 7, 2021

MEDIA ADVISORY: Ultragenyx Canada Announces Health Canada Approval of a Second Indication for Crysvita(TM) (Burosumab Injection) for the Treatment of Tumour Induced Osteomalacia in Adults

GlobeNewswire September 7, 2021

Ultragenyx to Participate in Panel at Citi's 16th Annual BioPharma Healthcare Conference

GlobeNewswire September 1, 2021

Ultragenyx Announces Approval of Dojolvi® (triheptanoin) in Brazil for the Treatment of Long-chain Fatty Acid Oxidation Disorders in Adults and Children

GlobeNewswire August 23, 2021

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire August 17, 2021

Ultragenyx to Participate in Gene Therapy Panel at Wedbush PacGrow Healthcare Conference

GlobeNewswire August 4, 2021

Ultragenyx Reports Second Quarter 2021 Financial Results and Corporate Update

GlobeNewswire August 2, 2021

Ultragenyx to Host Conference Call for Second Quarter 2021 Financial Results and Corporate Update

GlobeNewswire July 27, 2021

Ultragenyx Receives Orphan Drug Designation from FDA and European Commission for UX053, an Investigational mRNA-therapy for the Treatment of Glycogen Storage Disease Type III

GlobeNewswire July 27, 2021

Ultragenyx Appoints Corsee Sanders, Ph.D., to Board of Directors

GlobeNewswire June 30, 2021

GeneTx and Ultragenyx Receive Approval from U.K. Regulatory Agency to Begin Clinical Study of GTX-102 for the Treatment of Angelman Syndrome

GlobeNewswire June 10, 2021

Ultragenyx to Present at Goldman Sachs 42nd Annual Healthcare Conference

GlobeNewswire June 3, 2021

Ultragenyx to Present at Jefferies Virtual Healthcare Conference

GlobeNewswire May 26, 2021

GeneTx and Ultragenyx Receive Clearance from Health Canada to Begin Clinical Study of GTX-102 in Canada for the Treatment of Angelman Syndrome

GlobeNewswire May 19, 2021

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire May 18, 2021

Ultragenyx Announces Positive Multi-Year Durability Data from Ongoing Phase 1/2 Gene Therapy Studies and Data on HeLa 3.0 Manufacturing Platform at American Society of Gene & Cell Therapy 2021 Annual Meeting

GlobeNewswire May 14, 2021

Ultragenyx to Present at Bank of America Securities Healthcare Conference

GlobeNewswire May 10, 2021

Ultragenyx Reports First Quarter 2021 Financial Results and Corporate Update

GlobeNewswire May 4, 2021